Project Title: Developing a 3D bioprinting system for intraoperative skin regeneration
Inventia Skin is developing the Ligō skin printing robot to revolutionise the way we approach wound repair by enabling the rapid and precise delivery of regenerative cellular therapy products directly onto the wound site.
Inadequate healing after skin trauma is a major health problem with a high chance of scarring, long term debilitation and high cost of healthcare. The Ligō device is set to change these dire outcomes for millions of patients worldwide by printing cellular products in a precise and patient-specific manner, facilitating improved regenerative outcomes. This technology will transform skin regeneration and our current approach to wound management.
Inventia Skin has brought together a number of high profile scientists and physicians including world renowned skin surgeon and former Australian of the Year, Professor Fiona Wood, and leading bioprinting researcher, Professor Gordon Wallace. The partnership will endeavour to print a patient's own cells, embedded in an optimised matrix material, directly onto a wound site to accelerate and improve healing after skin injury.
The planned commencement of clinical trials by 2022 using this technology would represent a world first and firmly place Australia as a global leader in the emerging field of clinical bioprinting and skin regeneration which is expected to have a global market value of over $18 billion by 2021.
BMTH Round: Three
State: New South Wales
Project Partners: Inventia Life Science, University of Wollongong & University of Western Australia
- MTPConnect Grant: $1,000,000
- Industry Contribution: $1,425,729
Duration: October 2020 - May 2023
Visit Inventia Skin for more information | Twitter: @InventiaSkin | LinkedIn: Inventia Life Science
Contact: Julio Ribeiro